We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Corporate Advert

CBD in the UK: Predictions for 2021

For all the excitement, the UK’s CBD industry is actually facing a roadblock, writes Professor Mike Barnes.

Read More

US Cannabis Sales Stay Steady

Sales of cannabis have continued to stay at pre-pandemic levels in the US, according to the cannabis market research firm BDSA.

Read More

Colorado Further Adds to Its List of Acceptable Cannabis Pesticides

The Colorado Department of Agriculture has once again expanded its list of pesticides approved for use on cannabis crops.

Read More

New Zealand’s Cannabis Legalization Bill Could Do With Some Improvements, Say Addiction Researchers

Before the 'reefer-endum' arrives, the country's legalization bill could still benefit from a few edits, say leading addiction researchers.

Read More

Many Dispensaries Still Make “Unsupported Claims” That Cannabis Can Treat Opioid Use Disorder, Says Study

The study found that these claims were more common in US states that listed opioid use disorder as a qualifying condition for medical cannabis.

Read More

Thousands of Cannabis Vape Products Are Still Impounded in Massachusetts

To help decide what to do with the impounded products, state authorities are welcoming input from the public until July 15.

Read More

Medicinal Cannabis Access in the UK: What’s the Hold-up?

David Hardstaff of BCL Solicitors LLP discuss the issues surrounding legal access to medical cannabis in the UK, as outlined in a recent in-depth report.

Read More

Many CBD Products Still Don’t Contain Advertised Amounts, FDA Study Finds

Product testing conducted by the US Food and Drug Administration (FDA) has found that many CBD-infused products on sale in the United States are mislabeled, containing vastly differing amounts of CBD than advertised on the product packaging.

Read More

Canadian Hospitals Launch Medical Cannabis Trial

Conducted over six months, the study hopes to include 2,000 patients from across Canada who live with chronic pain, insomnia, anxiety, and depression.

Read More

Advertisement